{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"385"}],"title":"Alive"},{"measurements":[{"groupId":"OG000","value":"271"},{"groupId":"OG001","value":"280"}],"title":"Dead"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"647"},{"groupId":"OG001","value":"665"}],"units":"Participants"}],"description":"The time alive in months from study entry to last contact or death.","groups":[{"description":"Patients receive doxorubicin IV over approximately 15-30 minutes on day 1, cisplatin IV over 60-90 minutes on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I (Doxorubicin, Cisplatin, Paclitaxel)"},{"description":"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm II (Paclitaxel, Carboplatin)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible and treated patients. Data are reported from the second interim analysis.","reportingStatus":"POSTED","timeFrame":"Patients were assessed during treatment. Following completion of treatment, follow up was assessed every 3 months for 2 years, then every 6 months for 3 years and annually after for a maximum of 10 years.","title":"Number of Participants Alive at Time of Last Follow-up.","type":"PRIMARY","unitOfMeasure":"Participants"}